A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee

Completed · Phase 3 · Has a placebo group

Conditions studied: Obesity, Overweight, Osteo Arthritis Knee

In brief

The main purpose of this study is to evaluate the safety and efficacy of retatrutide once-weekly in participants who have obesity or are overweight and have osteoarthritis (OA) of the knee. The study will lasts about 77 weeks.

Key facts

Study ID

NCT05931367

Run by

Eli Lilly and Company

People needed

445

Starts

2023-08-01

Expected to finish

2025-11-14

Last updated by the study team

2026-01-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Have a body mass index (BMI) ≥27 kilogram/kg/m² at screening.
• Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight.
• Have index knee pain for >12 weeks prior to screening, and presence of index knee pain for >15 days over the previous month.
• Have knee X-ray with moderate radiographic changes (Kellgren-Lawrence Grade 2 or 3) per central reading at screening.
• Currently meets American College of Rheumatology (ACR) Criteria (clinical and radiological) for OA.

You may not qualify if…

• Have had steroid joint injections within 90 days of screening.
• Have had other joint injections and procedures within 6 months of screening.
• Have joint disease other than osteoarthritis.
• Have a self-reported or documented change in body weight >5 kg (11 pounds) within 90 days prior to screening.
• Have been taking weight loss drugs, including over-the-counter medications, within 90 days prior to screening.
• Have a prior or planned surgical treatment for obesity.
• Have diabetes mellitus.

Where it is running

• Arizona Research Center — Phoenix, Arizona, United States
• Artemis Institute for Clinical Research — San Diego, California, United States
• Chase Medical Research, LLC — Waterbury, Connecticut, United States
• Suncoast Research Group — Miami, Florida, United States
• North Georgia Clinical Research — Woodstock, Georgia, United States
• Elite Clinical Trials — Blackfoot, Idaho, United States
• Northwestern University — Chicago, Illinois, United States
• MedVadis Research Corporation — Waltham, Massachusetts, United States
• Great Lakes Research Group, Inc. — Bay City, Michigan, United States
• Clinvest Research LLC — Springfield, Missouri, United States
• Mercy Family Clinic — Dallas, Texas, United States
• Clinical Trials of Texas, Inc. — San Antonio, Texas, United States
• Northwest Clinical Research Center — Bellevue, Washington, United States
• Paratus Clinical Research Canberra — Bruce, Australian Capital Territory, Australia
• Paratus Clinical Research Western Sydney — Blacktown, New South Wales, Australia
• Emeritus Research — Botany, New South Wales, Australia
• Royal Brisbane and Women's Hospital — Brisbane, Queensland, Australia
• Core Research Group — Brisbane, Queensland, Australia
• CDH Research Institute — Maroochydore, Queensland, Australia
• Emeritus Research — Camberwell, Victoria, Australia
• Barwon Health — Geelong, Victoria, Australia
• C-health Research — Calgary, Alberta, Canada
• Eastern Health - General Hospital — St. John's, Newfoundland and Labrador, Canada
• Viable Clinical Research — Bridgewater, Nova Scotia, Canada
• Wharton Medical Clinic — Hamilton, Ontario, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.